Skip to main content

Advertisement

Fig. 4 | Journal for ImmunoTherapy of Cancer

Fig. 4

From: Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy

Fig. 4

| Combining CAI with DMF or 1-MT increased the number of tumor-infiltrating CD8+ T cells and downregulated PD-1 expression. BALB/c or C57BL/6 mice were subcutaneously injected with 1 × 106 tumor cells (C26 cells, B16 cells or 4 T1 cells, n = 6 in every group) and received the indicated drugs for 7 days after the day the tumor size reached 5 mm in diameter. T cells in the tumor microenvironment were sorted and analyzed by flow cytometry. a Representative flow cytometry plots showing the fraction of CD8+ T cells within the CD3+ TILs in the C26, B16- or 4 T1- tumor microenvironment. b CD8+ T cell numbers per gram of tumor in different groups. c The percentage of PD-1+CD8+ T cells within TILs in the tumor microenvironment. d, e and f The same measurements from the evaluation of the effects of another drug combination (CAI and 1-MT) in C26-, B16- or 4 T1- tumor bearing mice. Data are from three independent experiments, and the error bars represent the mean ± s.e.m. **p < 0.01 by one-way ANOVA (a-f)

Back to article page